RN Mobile Menu

Search form


Juvenile Arthritis

Juvenile Arthritis

JIA (©PuwadolJaturawutthichai/Shutterstock.com)

Researchers from the Netherlands compare three treatment options for patients with recent onset, non-systemic juvenile idiopathic arthritis.

(Child and adult hands ©PuwadolJaturawutthichai/ShutterStock.com)

Researchers writing in Annals of the Rheumatic Diseases say they have identified a link between juvenile idiopathic arthritis and adult rheumatoid arthritis.


Genetic risk factors for systemic juvenile idiopathic arthritis are uniquely different from other types of juvenile idiopathic arthritis, a study shows.

UAB research shows no “marked incremental increase in incident malignancies” after treatment with TNFi therapy as compared to malignancy rates associated with juvenile idiopathic arthritis.


In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.


Treg cells are more prevalent in patients with juvenile idiopathic arthritis and active inflammation, as compared to patients in remission.


Pregnant women with juvenile arthritis are at heightened risk of heart disease, new research finds.


Subscribe to Juvenile Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.